Literature DB >> 9275036

Cautionary tales of survival analysis: conflicting analyses from a clinical trial in breast cancer.

W M Gregory1, K Bolland, J Whitehead, R L Souhami.   

Abstract

Data from a completed randomized trial in breast cancer are used to demonstrate and quantify the variation in estimated survival curves and log-rank statistics at different times throughout a trial. False 'plateaux' are common, as are wide fluctuations in chi2 values obtained from the log-rank test when there are few events. We show how analyses conducted at different times can demonstrate different effects. Long follow-up is often necessary to allow correct interpretation of results. We discuss the assumption of proportional hazards and the consequences of making that assumption inappropriately. We show how checking whether hazards are proportional can help in avoiding erroneous conclusions.

Entities:  

Mesh:

Year:  1997        PMID: 9275036      PMCID: PMC2227982          DOI: 10.1038/bjc.1997.424

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  9 in total

1.  Interim analyses for monitoring clinical trials that do not materially affect the type I error rate.

Authors:  A L Gould
Journal:  Stat Med       Date:  1992-01-15       Impact factor: 2.373

2.  Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data.

Authors:  M S Pepe; T R Fleming
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

3.  The clinical importance of early stopping of randomized trials in cancer treatments.

Authors:  R L Souhami
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

4.  A reversal of fortune: practical problems in the monitoring and interpretation of an EORTC breast cancer trial.

Authors:  R Sylvester; H Bartelink; R Rubens
Journal:  Stat Med       Date:  1994 Jul 15-30       Impact factor: 2.373

5.  Tables of the number of patients required in clinical trials using the logrank test.

Authors:  L S Freedman
Journal:  Stat Med       Date:  1982 Apr-Jun       Impact factor: 2.373

6.  On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.

Authors:  P M Fayers; P A Cook; D Machin; N Donaldson; J Whitehead; A Ritchie; R T Oliver; P Yuen
Journal:  Stat Med       Date:  1994-11-15       Impact factor: 2.373

7.  Locally advanced breast cancer: the contribution of cytotoxic and endocrine treatment to radiotherapy. An EORTC Breast Cancer Co-operative Group Trial (10792).

Authors:  R D Rubens; H Bartelink; E Engelsman; J L Hayward; N Rotmensz; R Sylvester; E van der Schueren; J Papadiamantis; S D Vassilaros; J Wildiers
Journal:  Eur J Cancer Clin Oncol       Date:  1989-04

8.  Interim analyses and stopping rules in cancer clinical trials.

Authors:  J Whitehead
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

9.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

  9 in total
  4 in total

1.  Reporting of adjuvant breast cancer trials: when is the right time?

Authors:  Helena M Earl
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

2.  Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials.

Authors:  Ezzeldin M Ibrahim; Marwan R Al-Hajeili; Ali M Bayer; Omalkhair A Abulkhair; Ahmed A Refae
Journal:  Med Oncol       Date:  2017-06-15       Impact factor: 3.064

3.  Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.

Authors:  Gareth J Morgan; Faith E Davies; Walter M Gregory; Nigel H Russell; Sue E Bell; Alexander J Szubert; Nuria Navarro Coy; Gordon Cook; Sylvia Feyler; Jenny L Byrne; Huw Roddie; Claudius Rudin; Mark T Drayson; Roger G Owen; Fiona M Ross; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

4.  Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Authors:  R E Coleman; M Collinson; W Gregory; H Marshall; R Bell; D Dodwell; M Keane; M Gil; P Barrett-Lee; D Ritchie; A Bowman; V Liversedge; R H De Boer; J L Passos-Coelho; S O'Reilly; G Bertelli; J Joffe; J E Brown; C Wilson; J C Tercero; J Jean-Mairet; R Gomis; D Cameron
Journal:  J Bone Oncol       Date:  2018-09-27       Impact factor: 4.072

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.